ARTL vs. SPRB, NRSN, FLGC, HCWB, SNSE, IMNN, BGXX, AIM, HOTH, and CRVO
Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), HCW Biologics (HCWB), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
Artelo Biosciences vs.
Spruce Biosciences (NASDAQ:SPRB) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 9.1% of Spruce Biosciences shares are held by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Artelo Biosciences had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 1.00 beat Artelo Biosciences' score of 0.25 indicating that Spruce Biosciences is being referred to more favorably in the media.
Spruce Biosciences presently has a consensus price target of $3.90, suggesting a potential upside of 943.34%. Artelo Biosciences has a consensus price target of $5.50, suggesting a potential upside of 356.81%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Artelo Biosciences.
Artelo Biosciences received 7 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 76.67% of users gave Artelo Biosciences an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote.
Artelo Biosciences has lower revenue, but higher earnings than Spruce Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Spruce Biosciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Artelo Biosciences has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Artelo Biosciences' return on equity.
Summary
Spruce Biosciences beats Artelo Biosciences on 10 of the 18 factors compared between the two stocks.
Get Artelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artelo Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ARTL) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ARTL Stock Alerts